Frequency
Senior Columnist Adam Feuerstein re-examines the red flags in the Cell Genesys story so that when the same issues rear their ugly head in another biotech story investors will be better prepared.
10:00AM 10/20/08
Cell Genesys' 'news' this week doesn't do much to boost prospects for its prostate cancer vaccine.
10:41AM 02/23/08
Medarex's recent drop in stock price means the FDA isn't likely to approve its melanoma drug soon.
6:38PM 01/06/08
Chordiant inks a big deal with a telecom company.
9:21PM 12/27/07
ValueClick and NetSuite could move higher.
10:27AM 12/26/07
Failing a phase III trial is never a good thing. Don't believe a CEO's attempt to spin it otherwise.
1:44PM 12/21/07
RIMM benefited from the explosive demand for Blackberry's.
8:44PM 12/20/07
The stock gets crushed after the drug can't meet its endpoint.
4:12PM 12/20/07
It's still too early to be a Pain Therapeutics bull.
9:53AM 12/08/07
Companies making headlines today include Goldman and Hewlett Packard.
05:59AM 11/20/07
Our Experts' Take at RealMoney
However, option traders boost January calls.
4:37PM 11/21/08
This market is producing a few stocks that could represent exceptional opportunities.
3:03PM 11/21/08
More Experts' Takes
More popular tickers are indicated by scale.
